TY - JOUR
T1 - Proceedings from the First Global Artificial Intelligence in Gastroenterology and Endoscopy Summit
AU - Parasa, Sravanthi
AU - Wallace, Michael
AU - Bagci, Ulas
AU - Antonino, Mark
AU - Berzin, Tyler
AU - Byrne, Michael
AU - Celik, Haydar
AU - Farahani, Keyvan
AU - Golding, Martin
AU - Gross, Seth
AU - Jamali, Vafa
AU - Mendonca, Paulo
AU - Mori, Yuichi
AU - Ninh, Andrew
AU - Repici, Alessandro
AU - Rex, Douglas
AU - Skrinak, Kris
AU - Thakkar, Shyam J.
AU - van Hooft, Jeanin E.
AU - Vargo, John
AU - Yu, Honggang
AU - Xu, Ziyue
AU - Sharma, Prateek
N1 - Funding Information:
DISCLOSURE: The following authors disclosed financial relationships: M. Wallace: Consultant for Virgo Inc, Cosmo/Aries Pharmaceuticals, Anx Robotica, Covidien , GI Supply, Boston Scientific, Endokey, Endostart, and Microtek; stock in Virgo Inc; research grants from Cosmo/Aries Pharmaceuticals, Fujifilm , Boston Scientific , Olympus , Medtronic , and Ninepoint Medical; other compensation from Synergy Pharmaceuticals and Cook Medical . T. Berzin: Consultant for Wilson AI, Fujifilm, and Medtronic. M. Byrne: Chief executive officer for Satisfai Health; co-development agreement with Olympus in AI and colon polyps with Ai4gi. H. Celik, S. Gross: Consultant for Olympus. Y. Mori: Consultant and speaker for Olympus. A. Ninh: Financial and equity in and cofounder and chief executive officer for Docbot Inc. A. Repici: Consultant for Boston Scientific and Medtronic; research grant from Fujifilm. D. Rex: Consultant for Olympus, Boston Scientific, Covidien/Medtronic, Aries Pharmaceutical, Braintree Laboratories , Lumendl, Ltd, Norgine, Endokey, and GI Supply; research grants from Olympus, Endoaid, Medivators, and Eribe USA Inc; ownership in Satisfai Health. S.J. Thakkar: Consultant for Olympus and Boston Scientific. J. E. van Hooft: Consultant for Cook Medical, Boston Scientific, and Medtronic; research grants from Cook Medical and Abbott. P. Sharma: Consultant for Olympus and Boston Scientific; research grants from Cosmo Pharmaceuticals, CDx Laboratories, Erbe, Fujifilm, Medtronic, and US Endoscopy. All other authors disclosed no financial relationships.
Publisher Copyright:
© 2020 American Society for Gastrointestinal Endoscopy
PY - 2020/10
Y1 - 2020/10
N2 - Background and Aims: Artificial intelligence (AI), specifically deep learning, offers the potential to enhance the field of GI endoscopy in areas ranging from lesion detection and classification to quality metrics and documentation. Progress in this field will be measured by whether AI implementation can lead to improved patient outcomes and more efficient clinical workflow for GI endoscopists. The aims of this article are to report the findings of a multidisciplinary group of experts focusing on issues in AI research and applications related to gastroenterology and endoscopy, to review the current status of the field, and to produce recommendations for investigators developing and studying new AI technologies for gastroenterology. Methods: A multidisciplinary meeting was held on September 28, 2019, bringing together academic, industry, and regulatory experts in diverse fields including gastroenterology, computer and imaging sciences, machine learning, computer vision, U.S. Food and Drug Administration, and the National Institutes of Health. Recent and ongoing studies in gastroenterology and current technology in AI were presented and discussed, key gaps in knowledge were identified, and recommendations were made for research that would have the highest impact in making advances and implementation in the field of AI to gastroenterology. Results: There was a consensus that AI will transform the field of gastroenterology, particularly endoscopy and image interpretation. Powered by advanced machine learning algorithms, the use of computer vision in endoscopy has the potential to result in better prediction and treatment outcomes for patients with gastroenterology disorders and cancer. Large libraries of endoscopic images, “EndoNet,” will be important to facilitate development and application of AI systems. The regulatory environment for implementation of AI systems is evolving, but common outcomes such as colon polyp detection have been highlighted as potential clinical trial endpoints. Other threshold outcomes will be important, as well as clarity on iterative improvement of clinical systems. Conclusions: Gastroenterology is a prime candidate for early adoption of AI. AI is rapidly moving from an experimental phase to a clinical implementation phase in gastroenterology. It is anticipated that the implementation of AI in gastroenterology over the next decade will have a significant and positive impact on patient care and clinical workflows. Ongoing collaboration among gastroenterologists, industry experts, and regulatory agencies will be important to ensure that progress is rapid and clinically meaningful. However, several constraints and areas will benefit from further exploration, including potential clinical applications, implementation, structure and governance, role of gastroenterologists, and potential impact of AI in gastroenterology.
AB - Background and Aims: Artificial intelligence (AI), specifically deep learning, offers the potential to enhance the field of GI endoscopy in areas ranging from lesion detection and classification to quality metrics and documentation. Progress in this field will be measured by whether AI implementation can lead to improved patient outcomes and more efficient clinical workflow for GI endoscopists. The aims of this article are to report the findings of a multidisciplinary group of experts focusing on issues in AI research and applications related to gastroenterology and endoscopy, to review the current status of the field, and to produce recommendations for investigators developing and studying new AI technologies for gastroenterology. Methods: A multidisciplinary meeting was held on September 28, 2019, bringing together academic, industry, and regulatory experts in diverse fields including gastroenterology, computer and imaging sciences, machine learning, computer vision, U.S. Food and Drug Administration, and the National Institutes of Health. Recent and ongoing studies in gastroenterology and current technology in AI were presented and discussed, key gaps in knowledge were identified, and recommendations were made for research that would have the highest impact in making advances and implementation in the field of AI to gastroenterology. Results: There was a consensus that AI will transform the field of gastroenterology, particularly endoscopy and image interpretation. Powered by advanced machine learning algorithms, the use of computer vision in endoscopy has the potential to result in better prediction and treatment outcomes for patients with gastroenterology disorders and cancer. Large libraries of endoscopic images, “EndoNet,” will be important to facilitate development and application of AI systems. The regulatory environment for implementation of AI systems is evolving, but common outcomes such as colon polyp detection have been highlighted as potential clinical trial endpoints. Other threshold outcomes will be important, as well as clarity on iterative improvement of clinical systems. Conclusions: Gastroenterology is a prime candidate for early adoption of AI. AI is rapidly moving from an experimental phase to a clinical implementation phase in gastroenterology. It is anticipated that the implementation of AI in gastroenterology over the next decade will have a significant and positive impact on patient care and clinical workflows. Ongoing collaboration among gastroenterologists, industry experts, and regulatory agencies will be important to ensure that progress is rapid and clinically meaningful. However, several constraints and areas will benefit from further exploration, including potential clinical applications, implementation, structure and governance, role of gastroenterologists, and potential impact of AI in gastroenterology.
UR - http://www.scopus.com/inward/record.url?scp=85089247589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089247589&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2020.04.044
DO - 10.1016/j.gie.2020.04.044
M3 - Article
C2 - 32343978
AN - SCOPUS:85089247589
SN - 0016-5107
VL - 92
SP - 938-945.e1
JO - Gastrointestinal endoscopy
JF - Gastrointestinal endoscopy
IS - 4
ER -